Zunsemetinib: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 20 patientsc19early.org

Zunsemetinib for COVID-19

Serious outcome risk
Zunsemetinib
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)0%
Mortality (1)0%
RCTs (1)0%
Late (1)0%
00.511.5+
← Zunsemetinib
reduces riskIncreased
risk →
c19early.org
October 2026

Zunsemetinib COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Gan (DB RCT)0%1.00 · 0.07–13.87death1/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Zunsemetinib
reduces riskZunsemetinib
increases risk →
c19early.org
October 2026

Zunsemetinib COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Gan (DB RCT)0%1.00 · 0.07–13.871/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Zunsemetinib
reduces riskZunsemetinib
increases risk →
c19early.org
October 2026

Zunsemetinib COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Gan (DB RCT)0%1.00 · 0.07–13.87death1/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Zunsemetinib
reduces riskZunsemetinib
increases risk →
c19early.org
October 2026

Zunsemetinib COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Gan (DB RCT)0%1.00 · 0.07–13.87death1/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Zunsemetinib
reduces riskZunsemetinib
increases risk →
c19early.org
October 2026

Zunsemetinib COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Gan (DB RCT)0%1.00 · 0.07–13.871/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Zunsemetinib
reduces riskZunsemetinib
increases risk →